Histopath\

Question 1

Breast carcinomas (to evaluate response to hormone therapy)

a. ER, PR, HER2
b. CK 7 ad CK 20
c. CD15 and CD 30
d. Chromogranin and Synaptophysin
e. p63 and CK 5/6
f. Ki67
g. PAX8
h. GATA-3
i. P16

Answer 1

a

Question 2

Classic Hodgkins Lymphoma

a. ER, PR, HER2
b. CK 7 ad CK 20
c. CD15 and CD 30
d. Chromogranin and Synaptophysin
e. p63 and CK 5/6
f. Ki67
g. PAX8
h. GATA-3
i. P16

Answer 2

c

Question 3

Myoepithelial cells and basement membrane

a. ER, PR, HER2
b. CK 7 ad CK 20
c. CD15 and CD 30
d. Chromogranin and Synaptophysin
e. p63 and CK 5/6
f. Ki67
g. PAX8
h. GATA-3
i. P16

Answer 3

e

Question 4

Ovarian Carcinoma

a. ER, PR, HER2
b. CK 7 ad CK 20
c. CD15 and CD 30
d. Chromogranin and Synaptophysin
e. p63 and CK 5/6
f. Ki67
g. PAX8
h. GATA-3
i. P16

Answer 4

g

Question 5

Breast Carcinoma

a. ER, PR, HER2
b. CK 7 ad CK 20
c. CD15 and CD 30
d. Chromogranin and Synaptophysin
e. p63 and CK 5/6
f. Ki67
g. PAX8
h. GATA-3
i. P16

Answer 5

h

Question 6

Breast, non-muchous ovarian, lung, Colorectal ca

a. ER, PR, HER2
b. CK 7 ad CK 20
c. CD15 and CD 30
d. Chromogranin and Synaptophysin
e. p63 and CK 5/6
f. Ki67
g. PAX8
h. GATA-3
i. P16

Answer 6

b

Question 7

Neuroendocrine tumors

a. ER, PR, HER2
b. CK 7 ad CK 20
c. CD15 and CD 30
d. Chromogranin and Synaptophysin
e. p63 and CK 5/6
f. Ki67
g. PAX8
h. GATA-3
i. P16

Answer 7

d

Question 8

Access Tumor proliferation

a. ER, PR, HER2
b. CK 7 ad CK 20
c. CD15 and CD 30
d. Chromogranin and Synaptophysin
e. p63 and CK 5/6
f. Ki67
g. PAX8
h. GATA-3
i. P16

Answer 8

f

Question 9

HPV-related tumors

a. ER, PR, HER2
b. CK 7 ad CK 20
c. CD15 and CD 30
d. Chromogranin and Synaptophysin
e. p63 and CK 5/6
f. Ki67
g. PAX8
h. GATA-3
i. P16

Answer 9

i